100 HEP/ml Pricktestlösung.

DRUG4 trials

Sponsors

ROXALL Medizin GmbH, ROXALL Medizin GmbH, ROXALL Medizin GmbH, LETI Pharma S.L.U.

Conditions

Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinaeModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelineModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Phase 2

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy

CompletedCTIS2023-505567-37-00

ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to birch pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2023-08-22End: 2024-10-11Target: 30Updated: 2023-08-22

Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from grass pollen allergy

CompletedCTIS2023-505880-35-00

ROXALL Medizin GmbH, ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to grass pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2023-11-10End: 2024-11-07Target: 30Updated: 2023-11-15

Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from Olea europaea pollen allergy

CompletedCTIS2024-511383-88-00

ROXALL Medizin GmbHModerate-to-severe allergic rhinitis / rhinoconjunctivitis due to olive pollen for at least two years according to the Allergic Rhinitis and its Impact on Asthma (ARIA) guideline

Start: 2024-09-01End: 2025-10-14Target: 50Updated: 2024-07-11

Phase 3

A multicenter, double-blind, placebo-controlled, clinical trial to evaluate the efficacy and safety of two concentrations of a mixture of depigmented polymerized allergenic extracts of D. pteronyssinus and D. farinae, in patients suffering from allergic rhinoconjunctivitis with or without controlled asthma

Not yet recruitingCTIS2025-521230-29-00

LETI Pharma S.L.U.Allergic rhinoconjunctivitis to Dermatophagoides pteronyssinus and Dermatophagoides farinae

Target: 320Updated: 2025-12-05